Calamos Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Calamos Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,954	Closed	-$735K	–	228
2017 Q4	$735K	Buy	1,954 +460	+31%	+$186K	0.1%	139
2017 Q3	$668K	Buy	+1,494	New	+$711K	0.09%	158
2015 Q1	–	Sell	-4,479	Closed	-$1.84M	–	257
2014 Q4	$1.84M	Sell	4,479 -1,187	-21%	-$467K	0.53%	68
2014 Q3	$2.04M	Buy	5,666 +30	+0.5%	+$10.1K	0.59%	53
2014 Q2	$1.59M	Sell	5,636 -175	-3%	-$51.9K	0.45%	87
2014 Q1	$1.75M	Buy	5,811 +1,417	+32%	+$437K	0.52%	83
2013 Q4	$1.21M	Buy	4,394 +1,540	+54%	+$443K	0.37%	98
2013 Q3	$893K	Buy	2,854 +88	+3%	+$23.1K	0.29%	107
2013 Q2	$622K	Buy	+2,766	New	+$644K	0.22%	127

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Calamos Wealth Management's REGN Position: Q1 2018 in Review

Calamos Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 1,954 shares — an estimated $735K sold.

Calamos Wealth Management first reported a position in REGN in Q2 2013 and held it in 9 quarters. The position peaked at $2.04M in Q3 2014. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Calamos Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Calamos Wealth Management sold 1,954 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $735K.
Calamos Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Calamos Wealth Management's Regeneron Pharmaceuticals position peaked at $2.04M in Q3 2014.
620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Calamos Wealth Management's 13F filing for Q1 2018, filed 13 Apr 2018.